AAM report: Complex generics could save U.S. healthcare system $1.3B per year Based on estimates, generic competition in the United States for seven complex products in AAM's analysis would yield annual savings between $600 million and $1.7 billion, with a median savings estimate of $1.3 billion. FDA touts Generic Drug Program’s efforts to ensure supply amid COVID-19In 2020, the FDA approved or tentatively approved 948 generic drug applications, including 72 first generics. The FDA also approved 30 generics under the Competitive Generic Therapy. Slayback taps Dave Picard as chief commercial officer Dave Picard, formerly senior vice president of global generic pharmaceuticals at AmerisourceBergen, is joining Slayback as chief commercial officer. Akorn obtains FDA green light for loteprednol etabonate ophthalmic gel Loteprednol etabonate ophthalmic gel 0.5% had a market value of approximately $35 million for the 12 months ended December 2020, according to IQVIA. Glenmark gets FDA nod for generic Cleocin T Gel The Cleocin T Gel had a market value of approximately $73.8 million for the 12 months ended December 2020, according to IQVIA. Glenmark obtains FDA green light for generic Qudexy Qudexy XR capsules had a market value of about $120.8 million for the 12 month period endedDecember 2020, according to IQVIA. Virtual roundtable: State of the generics industry Executives from leading generics firms weigh in on what the future holds for the industry and what hurdles will have to be overcome. Alembic debuts generic Symmetrel Alembic's generic Symmetrel is available in a dosage strength of 100 mg in 100-count bottles. Lupin gets FDA nod for generic Kerydin Tavaborole topical solution had a market value of roughly $76 million, according to IQVIA December 2020 data. Lannett expands strategic relationship with HEC for biosimilar Aspart Lannett and HEC will co-develop biosimilar insulin Aspart, with Lannett possessing exclusive U.S. commercialization rights. First Previous 126 127 128 129 130 Next Last
